BioAge Labs, Inc. (BIOA) Stock
Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks
BioAge Labs, Inc. (BIOA) closed at USD 5.42 on 2026-10-14, a change of -31.3 % over the past year, with a market capitalization of USD 245.55M.
BioAge Labs, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 5.42 |
| 2026-10-13 | 5.57 |
| 2026-10-12 | 5.94 |
| 2026-10-09 | 6.34 |
| 2026-10-08 | 6.21 |
| 2026-10-07 | 6.26 |
| 2026-10-06 | 6.29 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
BioAge Labs, Inc. key figures
- Previous close
- USD 5.42 (2026-10-14)
- 1-year change
- -31.3 %
- Market cap
- USD 245.55M
- Enterprise value
- USD -70.36M
- P/E ratio (trailing)
- -2.33
- P/E ratio (forward)
- -2.14
- EPS (trailing)
- -2.30
- EPS (forward)
- -2.50
- PEG ratio
- n/a
- Price to book
- 0.65
- Revenue growth
- 1.6 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 4.67
- Employees
- 60
- Analyst consensus (third-party)
- buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for BioAge Labs, Inc. and compare it with other stocks.
Analyze BIOAAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell BioAge Labs, Inc. shares.